Author

N. Allain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

F. SALTEL· 3 shared V. Moreau· 3 shared N. Dugot-Senant· 2 shared A. Abou-Ammoud· 1 shared A. Abouhammoud· 1 shared A. Jabouille· 1 shared A. Pham-Ledart· 1 shared A. Uguen· 1 shared

Activity by Year

2020-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

F. SALTEL

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

The beta-catenin-target Fascin-1, altering hepatocyte differentiation, is a new marker of immature cells in hepatoblastomas

C. Gest, S. Sena, V. Neaud, R. Loesch, N. Dugot-Senant, L. Paysan, L. Piquet, T. Robbe, N. Allain, D. Dembele, C. Guettier, P. Bioulac-Sage, B. Le Bail, C. Grosset, F. SALTEL, , V. Moreau

The paper investigates the role of beta-catenin in hepatoblastomas, identifying Fascin-1 as a marker of immature cells linked to loss of hepatocyte differentiation.

bioRxiv · Apr 21, 2021Cancer Biology

Discoidin domain receptor 2 drives melanoma drug resistance through AXL-dependent phenotype switching

M. Sala, N. Allain, A. Jabouille, E. Henriet, A. Abou-Ammoud, A. Uguen, S. Di-Tommaso, D. Cyril, A.-A. Raymond, J.-W. Dupuy, E. Gerard, N. Dugot-Senant, B. Rousseau, J.-P. Merlio, A. Pham-Ledart, , F. Saltel

This study shows DDR2 drives melanoma drug resistance via AXL-dependent phenotype switching, suggesting DDR inhibition as a potential second-line treatment.

bioRxiv · Mar 26, 2021 · PreprintCancer Biology

DDR2 induces linear invadosome to promote angiogenesis in a fibrillar type I collagen context

A. Abouhammoud, S. Marais, N. Allain, Z. Ezzoukhry, V. Moreau, F. SALTEL

This study identifies DDR2 as a key receptor for collagen that promotes angiogenesis by enabling linear invadosome formation in endothelial cells.

bioRxiv · Apr 11, 2020 · PreprintCell Biology